Agilent Technologies Past Earnings Performance
Past criteria checks 2/6
Agilent Technologies has been growing earnings at an average annual rate of 7.7%, while the Life Sciences industry saw earnings growing at 18.5% annually. Revenues have been growing at an average rate of 8% per year. Agilent Technologies's return on equity is 20%, and it has net margins of 18.4%.
Key information
7.7%
Earnings growth rate
9.5%
EPS growth rate
Life Sciences Industry Growth | 26.8% |
Revenue growth rate | 8.0% |
Return on equity | 20.0% |
Net Margin | 18.4% |
Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Agilent Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Jan 24 | 6,735 | 1,236 | 1,553 | 478 |
31 Oct 23 | 6,833 | 1,240 | 1,578 | 481 |
31 Jul 23 | 6,994 | 1,133 | 1,589 | 486 |
30 Apr 23 | 7,040 | 1,351 | 1,591 | 484 |
31 Jan 23 | 6,930 | 1,323 | 1,585 | 473 |
31 Oct 22 | 6,848 | 1,254 | 1,578 | 467 |
31 Jul 22 | 6,659 | 1,328 | 1,552 | 464 |
30 Apr 22 | 6,527 | 1,263 | 1,548 | 461 |
31 Jan 22 | 6,445 | 1,205 | 1,571 | 455 |
31 Oct 21 | 6,319 | 1,210 | 1,562 | 441 |
31 Jul 21 | 6,142 | 990 | 1,562 | 426 |
30 Apr 21 | 5,817 | 925 | 1,464 | 405 |
31 Jan 21 | 5,530 | 810 | 1,404 | 396 |
31 Oct 20 | 5,339 | 719 | 1,395 | 397 |
31 Jul 20 | 5,223 | 691 | 1,377 | 398 |
30 Apr 20 | 5,236 | 683 | 1,446 | 407 |
31 Jan 20 | 5,236 | 764 | 1,405 | 406 |
31 Oct 19 | 5,163 | 1,071 | 1,358 | 404 |
31 Jul 19 | 5,090 | 1,072 | 1,343 | 406 |
30 Apr 19 | 5,019 | 1,117 | 1,290 | 402 |
31 Jan 19 | 4,987 | 1,140 | 1,301 | 395 |
31 Oct 18 | 4,914 | 316 | 1,322 | 387 |
31 Jul 18 | 4,809 | 298 | 1,284 | 372 |
30 Apr 18 | 4,720 | 237 | 1,269 | 362 |
31 Jan 18 | 4,616 | 196 | 1,235 | 354 |
31 Oct 17 | 4,472 | 684 | 1,205 | 341 |
31 Jul 17 | 4,394 | 633 | 1,173 | 330 |
30 Apr 17 | 4,324 | 582 | 1,167 | 329 |
31 Jan 17 | 4,241 | 509 | 1,159 | 326 |
31 Oct 16 | 4,202 | 462 | 1,174 | 325 |
31 Jul 16 | 4,126 | 476 | 1,184 | 324 |
30 Apr 16 | 4,096 | 465 | 1,175 | 317 |
31 Jan 16 | 4,040 | 466 | 1,170 | 317 |
31 Oct 15 | 4,038 | 438 | 1,189 | 327 |
31 Jul 15 | 4,046 | 306 | 1,189 | 340 |
30 Apr 15 | 4,041 | 256 | 1,184 | 347 |
31 Jan 15 | 4,066 | 204 | 1,196 | 353 |
31 Oct 14 | 4,048 | 232 | 1,199 | 358 |
31 Jul 14 | 4,723 | 435 | 1,325 | 434 |
30 Apr 14 | 5,366 | 540 | 1,490 | 518 |
31 Jan 14 | 6,110 | 666 | 1,654 | 604 |
31 Oct 13 | 3,894 | 225 | 1,184 | 337 |
31 Jul 13 | 6,831 | 938 | 1,866 | 700 |
30 Apr 13 | 6,902 | 1,013 | 1,861 | 692 |
Quality Earnings: AG8 has high quality earnings.
Growing Profit Margin: AG8's current net profit margins (18.4%) are lower than last year (19.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AG8's earnings have grown by 7.7% per year over the past 5 years.
Accelerating Growth: AG8's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: AG8 had negative earnings growth (-6.6%) over the past year, making it difficult to compare to the Life Sciences industry average (6.5%).
Return on Equity
High ROE: AG8's Return on Equity (20%) is considered low.